bronchiectasis

Summary

Summary: Persistent abnormal dilatation of the bronchi.

Top Publications

  1. Chang A, Bell S, Byrnes C, Grimwood K, Holmes P, King P, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust. 2010;193:356-65 pubmed
    Consensus recommendations for managing chronic suppurative lung disease (CSLD) and bronchiectasis, based on systematic reviews, were developed for Australian and New Zealand children and adults during a multidisciplinary workshop...
  2. Martínez García M, Soler Cataluña J, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140:1130-1137 pubmed publisher
    Previous studies have shown a high prevalence of bronchiectasis in patients with moderate to severe COPD. However, the factors associated with bronchiectasis remain unknown in these patients...
  3. Coeman M, van Durme Y, Bauters F, Deschepper E, Demedts I, Smeets P, et al. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. Ther Adv Respir Dis. 2011;5:377-86 pubmed publisher
    ..the efficacy and safety of low-dose neomacrolides as add-on therapy in patients with severe asthma and/or bronchiectasis and to identify predictors for therapeutic response...
  4. Montella S, Maglione M, Bruzzese D, Mollica C, Pignata C, Aloj G, et al. Magnetic resonance imaging is an accurate and reliable method to evaluate non-cystic fibrosis paediatric lung disease. Respirology. 2012;17:87-91 pubmed publisher
    ..MRI and HRCT scans were also assessed using a modified Helbich score. Bronchiectasis, mucous plugging, peribronchial wall thickening, consolidation, bullae, abscesses and emphysema were detected ..
  5. Chang A, Marsh R, Smith Vaughan H, Hoffman L. Emerging drugs for bronchiectasis. Expert Opin Emerg Drugs. 2012;17:361-78 pubmed publisher
    The global burden of disease due to bronchiectasis is high, disproportionately impacting developing countries and disadvantaged populations...
  6. Tambascio J, Lisboa R, Passarelli R, Martinez J, Gastaldi A. Adhesiveness and purulence of respiratory secretions: implications for mucociliary transport in patients with bronchiectasis. J Bras Pneumol. 2010;36:545-53 pubmed
    ..the transport properties of respiratory secretions, classified by selected parameters, in individuals with bronchiectasis unrelated to cystic fibrosis...
  7. Sly P, Gangell C, Chen L, Ware R, Ranganathan S, Mott L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368:1963-70 pubmed
    b>Bronchiectasis develops early in the course of cystic fibrosis, being detectable in infants as young as 10 weeks of age, and is persistent and progressive...
  8. Maglione M, Bush A, Montella S, Mollica C, Manna A, Esposito A, et al. Progression of lung disease in primary ciliary dyskinesia: is spirometry less accurate than CT?. Pediatr Pulmonol. 2012;47:498-504 pubmed publisher
    ..01). Age was significantly related to HRCT total (r?=?0.5; P?=?0.02) and bronchiectasis scores (r?=?0.5; P?=?0.02). At both evaluations, HRCT total score correlated with FEV(1) (r?=?-0.5, P?=?0...
  9. Martínez García M, Máiz Carro L, Catalán Serra P. [Treatment of non-cystic fibrosis bronchiectasis]. Arch Bronconeumol. 2011;47:599-609 pubmed publisher
    b>Bronchiectasis is currently growing in importance due to both the increase in the number of diagnoses made as well as the negative impact that its presence has on the baseline disease that generates it...

More Information

Publications62

  1. Pasteur M, Bilton D, Hill A. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65 Suppl 1:i1-58 pubmed publisher
    The diagnosis, investigation and particularly management of bronchiectasis has been largely empirical and the subject of relatively few controlled clinical trials...
  2. Chang A, Grimwood K, Robertson C, Wilson A, Van Asperen P, O Grady K, et al. Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. Trials. 2012;13:156 pubmed publisher
    Despite bronchiectasis being increasingly recognised as an important cause of chronic respiratory morbidity in both indigenous and non-indigenous settings globally, high quality evidence to inform management is scarce...
  3. Valery P, Morris P, Grimwood K, Torzillo P, Byrnes C, Masters I, et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. BMC Pediatr. 2012;12:122 pubmed
    The prevalence of chronic suppurative lung disease (CSLD) and bronchiectasis unrelated to cystic fibrosis (CF) among Indigenous children in Australia, New Zealand and Alaska is very high...
  4. Hare K, Grimwood K, Leach A, Smith Vaughan H, Torzillo P, Morris P, et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr. 2010;157:1001-5 pubmed publisher
    ..strain diversity, and concordance of pathogens between upper and lower airways are higher in children with bronchiectasis than in those with non-bronchiectatic conditions...
  5. Ramakrishnan V, Ferril G, Suh J, Woodson T, Green T, Kingdom T. Upper and lower airways associations in patients with chronic rhinosinusitis and bronchiectasis. Int Forum Allergy Rhinol. 2013;3:921-7 pubmed publisher
    b>Bronchiectasis is an uncommon disease of the lower airways characterized by bronchial wall destruction and permanent bronchiolar dilation...
  6. Serisier D, Bilton D, De Soyza A, Thompson P, Kolbe J, Greville H, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68:812-7 pubmed publisher
    ..antibiotics by inhalation to Pseudomonas aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical extension of treatment strategies successfully developed in CF bronchiectasis...
  7. Athanazio R, Rached S, Rohde C, Pinto R, Fernandes F, Stelmach R. Should the bronchiectasis treatment given to cystic fibrosis patients be extrapolated to those with bronchiectasis from other causes?. J Bras Pneumol. 2010;36:425-31 pubmed
    To profile the characteristics of adult patients with bronchiectasis, drawing comparisons between cystic fibrosis (CF) patients and those with bronchiectasis from other causes in order to determine whether it is rational to extrapolate ..
  8. Caylak H, Genc O, Kavakli K, Gurkok S, Gozubuyuk A, Yucel O, et al. Surgical management of bronchiectasis: a collective review of 339 patients with long-term follow-up. Thorac Cardiovasc Surg. 2011;59:479-83 pubmed publisher
    The incidence of bronchiectasis has decreased significantly in developed countries due to successful control of childhood infections...
  9. Hare K, Leach A, Morris P, Smith Vaughan H, Torzillo P, Bauert P, et al. Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis. Int J Antimicrob Agents. 2012;40:365-9 pubmed publisher
    Indigenous Australian children have increased rates of bronchiectasis. Despite a lack of high-level evidence on effectiveness and antibiotic resistance, these children often receive long-term antibiotics...
  10. Chang A, Byrnes C, Everard M. Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis. Paediatr Respir Rev. 2011;12:97-103 pubmed publisher
    Current diagnostic labelling of childhood bronchiectasis by radiology has substantial limitations...
  11. Chalmers J, McHugh B, Doherty C, Smith M, Govan J, Kilpatrick D, et al. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respir Med. 2013;1:224-32 pubmed publisher
    ..We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis. We recruited patients with non-cystic fibrosis bronchiectasis and age-matched and sex-matched controls at a ..
  12. Einsiedel L, Fernandes L, Spelman T, Steinfort D, Gotuzzo E. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis. 2012;54:43-50 pubmed publisher
    Recent studies suggest that infection with human T-lymphotropic virus 1 (HTLV-1) might be associated with bronchiectasis among Indigenous Australians...
  13. Rademacher J, Welte T. Bronchiectasis--diagnosis and treatment. Dtsch Arztebl Int. 2011;108:809-15 pubmed publisher
    Radiologically evident bronchiectasis is seen in 30% to 50% of patients with advanced chronic obstructive pulmonary disease (COPD). As COPD is now becoming more common around the world, bronchiectasis is as well...
  14. Hare K, Binks M, Grimwood K, Chang A, Leach A, Smith Vaughan H. Culture and PCR detection of Haemophilus influenzae and Haemophilus haemolyticus in Australian Indigenous children with bronchiectasis. J Clin Microbiol. 2012;50:2444-5 pubmed publisher
    ..90% of nasopharyngeal specimens and 100% of lower-airway specimens from 84 Indigenous Australian children with bronchiectasis had phenotypic NTHI isolates confirmed as H...
  15. Bochet M, Garin N, Janssens J, Gerstel E. [Is there a role for prophylactic antibiotic treatment with macrolides in bronchiectasis?]. Rev Med Suisse. 2011;7:308, 310-2 pubmed
    Prophylactic antibiotherapy with macrolides is commonly used to prevent bronchiectasis exacerbations...
  16. Bagheri R, Haghi S, Fattahi Masoum S, Bahadorzadeh L. Surgical management of bronchiectasis: analysis of 277 patients. Thorac Cardiovasc Surg. 2010;58:291-4 pubmed publisher
    b>Bronchiectasis is a permanent irreversible dilatation of the bronchial wall, often arising from inadequate treatment of a pulmonary infection...
  17. Novosad S, Barker A. Chronic obstructive pulmonary disease and bronchiectasis. Curr Opin Pulm Med. 2013;19:133-9 pubmed publisher
    Chronic obstructive pulmonary disease (COPD) and bronchiectasis are two different but related diseases that occur separately, but can coexist...
  18. Kapur N, Grimwood K, Masters I, Morris P, Chang A. Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol. 2012;47:300-7 pubmed publisher
    Infection and inflammation are important in the pathogenesis of bronchiectasis. However, there are few published data describing the lower airway microbiology and cellularity in children...
  19. Chalmers J, McHugh B, Docherty C, Govan J, Hill A. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax. 2013;68:39-47 pubmed publisher
    ..of this study was to determine the frequency and clinical importance of vitamin-D deficiency in patients with bronchiectasis. 25-hydroxyvitamin-D was measured by immunoassay in 402 stable patients with bronchiectasis...
  20. Kwak H, Moon J, Choi Y, Kim T, Sohn J, Yoon H, et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J Exp Med. 2010;222:237-42 pubmed
    b>Bronchiectasis is one of the common chronic respiratory diseases and associated with respiratory morbidity and mortality. However, neither its prevalence nor its etiology is well-defined...
  21. Martínez García M, Soler Cataluña J, Catalán Serra P, Román Sánchez P, Tordera M. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141:461-468 pubmed publisher
    ..in a single inhaler compared with high-dose budesonide treatment in patients with non-cystic fibrosis (non-CF) bronchiectasis. This is a 12-month randomized, double-blind, parallel-groups clinical trial, to run in 40 patients with non-..
  22. O Grady K, Torzillo P, Chang A. Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life. Med J Aust. 2010;192:586-90 pubmed
    To describe the epidemiology of acute lower respiratory infection (ALRI) and bronchiectasis in Northern Territory Indigenous infants hospitalised in the first year of life...
  23. Haworth C, Foweraker J, Wilkinson P, Kenyon R, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189:975-82 pubmed publisher
    ..exacerbation frequency, a more rapid decline in lung function, and increased mortality in patients with bronchiectasis. To perform a randomized placebo-controlled study assessing the efficacy and safety of inhaled colistin in ..
  24. Martínez García M, de la Rosa Carrillo D, Soler Cataluña J, Donat Sanz Y, Serra P, Lerma M, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:823-31 pubmed publisher
    The prevalence of bronchiectasis is high in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and it has been associated with exacerbations and bacterial colonization...
  25. García M, Cataluña J. [Chronic obstructive pulmonary disease and bronchiectasias]. Arch Bronconeumol. 2010;46 Suppl 3:11-7 pubmed publisher
    ..Lastly, some physiopathologic hypotheses that remain to be demonstrated suggest a causal relation between the two diseases in which COPD, especially severe forms, would constitute a risk factor for the formation of bronchiectasias. ..
  26. Smith M. Non-cystic fibrosis bronchiectasis. J R Coll Physicians Edinb. 2011;41:132-9; quiz 139 pubmed publisher
    b>Bronchiectasis is a chronic debilitating condition...
  27. Jordan T, Spencer E, Davies P. Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology. 2010;15:623-8 pubmed publisher
    Both tuberculosis and bronchiectasis carry a significant burden worldwide in terms of morbidity and mortality, as well as financial, especially in the developing world...
  28. Grimwood K. Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr Respir Rev. 2011;12:111-8 pubmed publisher
    b>Bronchiectasis in children without cystic fibrosis is most common in socioeconomically disadvantaged communities. Recurrent pneumonia in early childhood and defective pulmonary defences are important risk factors...
  29. Feldman C. Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med. 2011;32:535-46 pubmed publisher
    Non-cystic fibrosis (CF) bronchiectasis is a common, potentially serious, condition...
  30. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J. 2010;86:493-501 pubmed publisher
    b>Bronchiectasis is permanently dilated airways caused by chronic bronchial inflammation secondary to inappropriate clearance of various micro-organisms and recurrent infections in the airways...
  31. Liu J, Zhong X, He Z, Zhong D, Bai J, Zhang J, et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35:824-7 pubmed
    ..the impact of treatment with low dose roxithromycin on clinical symptoms and CT scores in patients with stable bronchiectasis. Fifty patients with bronchiectasis in stable condition were randomly assigned to a control group and a ..
  32. Seitz A, Olivier K, Adjemian J, Holland S, Prevots D. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432-439 pubmed publisher
    b>Bronchiectasis is a potentially serious condition characterized by permanent and abnormal widening of the airways, the prevalence of which is not well described...
  33. Rowan S, Bradley J, Bradbury I, Lawson J, Lynch T, Gustafsson P, et al. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med. 2014;189:586-92 pubmed publisher
    In bronchiectasis there is a need for improved markers of lung function to determine disease severity and response to therapy.
  34. McShane P, Naureckas E, Tino G, Strek M. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188:647-56 pubmed publisher
    There is renewed interest in non-cystic fibrosis bronchiectasis, which is a cause of significant morbidity in adults and can be diagnosed by high-resolution chest computed tomography scan...
  35. Kapur N, Masters I, Morris P, Galligan J, Ware R, Chang A. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol. 2012;47:68-75 pubmed publisher
    Exacerbations in non-cystic fibrosis (CF) bronchiectasis are associated with worsening lung functions and quality of life. A standardized definition of exacerbation could improve clinical care and research...
  36. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-7 pubmed publisher
    ..increase lung function, and improve health-related quality of life in patients with non-cystic fibrosis bronchiectasis. We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand...
  37. Hill A, Pasteur M, Cornford C, Welham S, Bilton D. Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. Prim Care Respir J. 2011;20:135-40 pubmed publisher
    ..Thoracic Society (BTS) has recently published a guideline for the management of non-cystic fibrosis (non-CF) bronchiectasis in children and adults. This paper summarises the key recommendations applicable to the primary care setting...
  38. Seitz A, Olivier K, Steiner C, Montes de Oca R, Holland S, Prevots D. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest. 2010;138:944-9 pubmed publisher
    Current data on bronchiectasis prevalence, trends, and risk factors are lacking; such data are needed to estimate the burden of disease and for improved medical care and public health resource allocation...
  39. Koh W, Choi G, Lee S, Park Y, Lee N, Shin S. First case of Segniliparus rotundus pneumonia in a patient with bronchiectasis. J Clin Microbiol. 2011;49:3403-5 pubmed publisher
    We report the first case of Segniliparus rotundus pneumonia in an adult with non-cystic fibrosis bronchiectasis. All isolates were identified as S. rotundus by 16S rRNA gene sequencing and rpoB PCR-restriction analysis...
  40. Kapur N, Masters I, Newcombe P, Chang A. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest. 2012;141:1018-1024 pubmed publisher
    The burden of disease in children with non-cystic fibrosis (non-CF) bronchiectasis is unknown...
  41. Anwar G, McDonnell M, Worthy S, Bourke S, Afolabi G, Lordan J, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med. 2013;107:1001-7 pubmed publisher
    b>Bronchiectasis is the outcome of a number of different airway insults. Very few studies have characterised the aetiology and utility of a dedicated screening proforma in adult patients attending a general bronchiectasis clinic...
  42. Altenburg J, de Graaff C, Stienstra Y, Sloos J, van Haren E, Koppers R, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251-9 pubmed publisher
    Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF bronchiectasis.
  43. Serisier D, Martin M, McGuckin M, Lourie R, Chen A, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309:1260-7 pubmed publisher
    Macrolide antibiotics such as erythromycin may improve clinical outcomes in non-cystic fibrosis (CF) bronchiectasis, although associated risks of macrolide resistance are poorly defined...
  44. Metersky M. New treatment options for bronchiectasis. Ther Adv Respir Dis. 2010;4:93-9 pubmed publisher
    Therapies shown to be effective in cystic fibrosis are often provided to patients with bronchiectasis, without definitive evidence of benefit...
  45. Rogers G, van der Gast C, Cuthbertson L, Thomson S, Bruce K, Martin M, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013;68:731-7 pubmed publisher
    Despite the potentially important roles for infection in adult non-cystic fibrosis (CF) bronchiectasis disease progression, the bacterial species present in the lower airways of these patients is poorly characterised.
  46. Bilton D, Daviskas E, Anderson S, Kolbe J, King G, Stirling R, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013;144:215-225 pubmed publisher
    Inhaled dry powder mannitol enhanced mucus clearance and improved quality of life over 2 weeks in non-cystic fibrosis bronchiectasis. This study's objective was to investigate the efficacy and safety of dry powder mannitol over 12 weeks.
  47. Serisier D, Martin M. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med. 2011;105:946-9 pubmed publisher
    Macrolide antibiotics are increasingly prescribed for subjects with non-cystic fibrosis (CF) bronchiectasis, an empiric extension of their proven efficacy in CF...
  48. Hester K, MacFarlane J, Tedd H, Jary H, McAlinden P, Rostron L, et al. Fatigue in bronchiectasis. QJM. 2012;105:235-40 pubmed publisher
    Fatigue is a complex, disabling symptom in non-CF bronchiectasis (nCF-Br). Fatigue can be formally measured using the validated fatigue impact scale (FIS)...
  49. Murray M, Govan J, Doherty C, Simpson A, Wilkinson T, Chalmers J, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183:491-9 pubmed publisher
    b>Bronchiectasis is a chronic debilitating disease with few evidence-based long-term treatments...
  50. Boddana P, Webb L, Unsworth J, Brealey M, Bingham C, Harper S. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon?. Clin Transplant. 2011;25:417-9 pubmed publisher
    ..Chronic pulmonary infection and hypogammaglobulinemia predispose to bronchiectasis, and we aimed to establish the incidence and clinical pattern of this condition within our MMF-treated renal ..
  51. Puechal X, Bienvenu T, Genin E, Berthelot J, Sibilia J, Gaudin P, et al. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis. Ann Rheum Dis. 2011;70:653-9 pubmed publisher
    In cystic fibrosis, mutations of the CFTR gene lead to diffuse bronchiectasis (DB)...
  52. Chalmers J, Smith M, McHugh B, Doherty C, Govan J, Hill A. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186:657-65 pubmed publisher
    The vicious cycle hypothesis of bronchiectasis argues that bacterial colonization leads to airway inflammation and progressive lung damage...
  53. Savelev S, Perry J, Bourke S, Jary H, Taylor R, Fisher A, et al. Volatile biomarkers of Pseudomonas aeruginosa in cystic fibrosis and noncystic fibrosis bronchiectasis. Lett Appl Microbiol. 2011;52:610-3 pubmed publisher
    ..Patients were recruited from specialist bronchiectasis and cystic fibrosis clinics. The gold standard for diagnosing Ps...